Sponsor	Phase
AstraZeneca	Phase 2
University of Washington	Phase 2
Merck Sharp & Dohme Corp.	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	VELBAN	vinblastine sulfate	INJECTABLE;INJECTION	012665-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 24, 2026

Executive summary

VELBAN is a legacy bortezomib brand used in oncology and supported by a mature, largely generic-competitive market for bortezomib. Near-term financial performance is driven by brand-to-generic share erosion, channel inventory and pricing, and site-of-care and regimen preference rather than new clinical adoption.
Financial trajectory is shaped by patent and exclusivity timing, generic entry waves, and ongoing biosurveillance-like pharmacovigilance and safety communications typical for proteasome inhibitor portfolios.
Net revenue outcomes for VELBAN specifically track U.S. and ex-U.S. distribution strategy, contracting outcomes, and competition from other bortezomib products (including subcutaneous alternatives where available), which pressure ASP and limit unit growth.
The forward revenue curve depends on how quickly payers move to lowest-cost bortezomib options, how hospitals rationalize formularies by administration route and acquisition cost, and whether manufacturers maintain sufficient supply during dosing cycles.

What is VELBAN (bortezomib) and how is it sold in oncology markets?

VELBAN is a bortezomib brand name. Bortezomib is a proteasome inhibitor used in hematologic malignancies, most commonly multiple myeloma and mantle cell lymphoma, depending on regulatory labeling by jurisdiction.

How do product form factor and administration route affect demand?

Bortezomib demand is sensitive to:

Route of administration (IV vs subcutaneous where supported by labeling in a market)
Clinical workflow fit in infusion centers vs hospital oncology pharmacies
Patient scheduling in 3-week and 4-week treatment cycles common for myeloma regimens

When payers compare products, they rarely isolate “brand”; they compare total acquisition cost plus administration time, pharmacy handling, and nursing workflow. Brands that align with preferred administration pathways typically hold share longer.

Which patient segments drive utilization?

For most bortezomib markets, utilization concentrates in:

Relapsed/refractory multiple myeloma
Newly diagnosed multiple myeloma when included in standard combination regimens
Mantle cell lymphoma lines where bortezomib remains a therapy option

Segment mix influences gross-to-net because hematology oncology has high contracting intensity, discounting, and bundled reimbursement dynamics.

What market dynamics shape VELBAN pricing, ASP, and gross-to-net?

How do hospital contracting and payer pressure shift VELBAN economics?

Hospital acquisition contracting for oncology injectables is typically driven by:

GPO leverage and wholesaler rebates
Formulary tiering (preferred vs nonpreferred proteasome inhibitors)
Budget impact at the service line level
State Medicaid and commercial PBM rebates for branded products

As generics or competing low-cost products gain traction, VELBAN revenue usually reflects:

Lower ASP via contract repricing
Higher rebate burden to defend shelf position
Volume resilience that does not translate into revenue growth, because unit gains can be offset by price declines

What competitive factors matter most for bortezomib brands?

Key competition drivers:

Multiple “bortezomib products” within the same molecule class, including authorized brands and generics
Subcutaneous preference in some markets because it changes administration workflow and patient throughput
Supply reliability and lot-level availability during peak dosing periods
Therapy-line positioning as clinicians shift to later-generation regimens (immunomodulatory drugs, monoclonal antibodies, and emerging combinations)

In a mature molecule market, financial performance is more about share of use within bortezomib-treated lines than it is about expanding total treated populations.

How does VELBAN’s financial trajectory typically evolve across patent and generic entry cycles?

The standard revenue curve in mature oncology injectables

For legacy brands like VELBAN, market evolution generally follows:

Peak brand period: strong utilization with limited low-cost alternatives
First erosion phase: initial generic or competing branded share gains, begins ASP pressure
Sustained erosion: multiple entrants, increasing price compression, reduced gross margins
Stabilization or exit: if the brand still survives through contracting and niche positioning, revenue stabilizes at a smaller base; otherwise it declines steeply

What “financial trajectory” indicators map to these phases?

Institutional investors and management teams typically monitor:

Revenue growth rate vs unit volume
Gross margin trend (rebate and manufacturing cost inflation offsets volume only partially)
Channel inventory (pull-through vs sell-in)
Contracted pricing changes at major accounts
Number of competing SKUs on formularies (often more important than total generic count)

What patents protect VELBAN (bortezomib) and how does exclusivity expiry influence sales?

Which patent categories matter for legacy bortezomib brands?

For bortezomib brands, patent estate impact typically comes from:

Drug substance and compositions
Formulations and concentration-specific compositions
Manufacturing process
Method-of-use (indications and combination regimens)
Orange Book-listed formulation and process patents that can block or delay FDA-legal generic entry

Once key Orange Book listed patents expire or are invalidated/settled, generic manufacturers can enter via ANDA pathways, driving rapid pricing drops.

What is the practical sales impact when exclusivity ends?

When patent barriers fall:

Generic availability increases quickly
Hospitals convert to lowest-cost preferred product
Brands like VELBAN face share loss even if clinicians remain comfortable with the original product
Revenue often declines even with stable total bortezomib patient counts

When do generics and competing bortezomib products typically enter, and what is the share-loss pattern?

Typical entry timing dynamics

Even with identical molecule endpoints, entry timing can vary by:

ANDA approval dates
Launch sequencing by manufacturer
Distribution and contracting readiness
Regulatory labeling scope
Supply ramp performance

What share-loss pattern is common?

In oncology injectables with direct therapeutic equivalence:

Share loss is often front-loaded after multiple entrants gain traction
Brands can sometimes retain share where they are still preferred in some systems due to:
- better conversion economics under specific contracts
- established procurement agreements
- supply continuity

Still, overall revenue typically declines faster than unit declines because of price compression.

What Paragraph IV or ANDA-related litigation risks exist for VELBAN (bortezomib)?

Litigation channels that affect brand revenue

For mature oncology brands, litigation can influence revenue through:

Carve-outs from FDA approval tied to patent disputes
Automatic stay impacts on generic launch
Settlement agreements that define launch dates

What is the practical relevance to revenue trajectory?

From a financial standpoint:

Litigation can create short-term revenue lift if it delays generic launch
Once settlements allow entry, brand revenue typically accelerates decline around the first generic shipment waves

What is the Orange Book status of VELBAN (bortezomib), and how does it affect FDA generic approval?

For U.S. brand drugs, the Orange Book lists patents that may be asserted against ANDAs. The status determines:

whether generics can file with a “paragraph” certification (I-IV)
whether an approval is blocked or stayed
whether the brand can enforce exclusivity through patent law

In bortezomib markets, Orange Book status usually matters less for long-run fundamentals than the market reality: most customers buy through contracted pricing once multiple equivalents exist.

How does VELBAN compare with competing bortezomib products on administration and formulary fit?

What differentiates bortezomib products economically?

Formulary decisions reflect:

Acquisition cost
Administration workflow (IV vs SC where applicable in a market)
Dosing schedule convenience
Waste profile and vial utilization
Handling requirements for reconstitution and storage

Which differentiation tends to matter after generic entry?

Once generics are present, differentiation mostly becomes:

contracting and supply
distribution coverage
account-level switching friction
route-of-administration preference where enabled by labeling and clinical standards

Clinical preference alone rarely sustains brand revenue when multiple equivalent low-cost options exist.

How do manufacturing and supply constraints affect VELBAN revenue?

What bottlenecks can create revenue volatility?

On injectable oncology products, revenue can swing due to:

active ingredient supply and purification batch variability
sterile fill-finish line constraints
packaging component availability
lot-release delays and QC findings

How supply constraints translate to financial outcomes

If supply is tight:

hospitals may stock lower quantities of nonpreferred products
procurement can shift to available alternatives
brand revenue may rise in the short term but often at the cost of longer-term share loss if customers substitute

In mature markets, persistent constraints can cause durable share loss.

What commercial strategies determine whether VELBAN holds share?

The main share-management levers

Brands typically rely on:

National and IDN contracting to secure “preferred” status
Account-specific rebate structures to retain oncology formulary inclusion
Inventory planning for predictable dosing cycles
Pharmacovigilance and risk communication consistency to maintain stakeholder confidence

What strategy is least effective post-generic entry?

Heavy discounting alone rarely restores long-term revenue if:

multiple low-cost equivalents are approved and fully stocked
procurement processes already switched to lowest-cost options
hospital pharmacy automation and ordering systems routinize substitution

What is VELBAN’s competitive landscape and revenue exposure profile?

Revenue exposure by region and channel

Revenue typically correlates with:

U.S. vs ex-U.S. distribution (different pricing/reimbursement regimes)
wholesale vs direct-to-hospital contracting intensity
extent of tendering and price controls in specific markets

Competitive density matters more than total number of entrants

A market with:

multiple authorized products
multiple generics
strong subcutaneous alternatives where preferred will compress pricing faster than a market with fewer equivalents.

Key takeaways on VELBAN market dynamics and financial trajectory

VELBAN’s financial trajectory is driven by mature-market bortezomib economics: contracting, rebate burden, and generic-led price compression.
Revenue growth, when it occurs, comes mainly from share stabilization and supply continuity, not from category expansion.
Generic entry waves and settlement-driven launch dates tend to produce stepwise ASP declines and front-loaded share losses.
Long-run performance hinges on whether VELBAN maintains preferred positioning in major accounts through contracting leverage and administration workflow fit.
The competitive outlook remains structurally challenging for a legacy brand unless differentiated advantages persist at the account level after generic availability.

FAQs

1) How does bortezomib brand revenue typically change after the first generic launch?

Typically, revenue declines quickly due to rapid procurement switching, with ASP compression outpacing unit volume changes.

2) Do hospitals switch from VELBAN to generic bortezomib immediately after approvals?

Switching accelerates once generics are stocked and contracts are renegotiated; timing varies by IDN formulary committees and procurement lead times.

3) Which matters more for net revenue, unit demand or contracting economics?

In mature oncology injectables, contracting economics usually drive net revenue because rebates and ASP repricing determine gross-to-net more than incremental unit demand.

4) Can supply constraints improve brand pricing in the short term?

They can, but persistent substitution risk and inventory decisions often create longer-term share damage that outweighs short-term pricing benefits.

5) What structural factors determine whether a legacy oncology brand stabilizes?

Stable positioning depends on entrenched preferred status in key accounts, low switching friction, reliable supply, and administration fit that reduces total cost in real-world workflows.

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
U.S. Food and Drug Administration. (n.d.). Drug Approval Reports and Databases. https://www.fda.gov/drugs/drug-approvals-and-databases

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	34
Patent Applications:	5,161
DailyMed Link:	VELBAN at DailyMed

AI Deep Research

Questions you can ask:

Summary for VELBAN

Recent Clinical Trials for VELBAN